Enovis Corporation reported a net sales increase of 5.4% for the first quarter of 2026, reaching $589.2 million compared to $558.8 million in the same period of 2025. The growth was driven by a 3.3% increase in existing business sales, favorable foreign currency translation effects, and contributions from recent acquisitions. However, this was partially offset by a $12.7 million decline in sales due to the divestiture of the Dr. Comfort Footcare Solutions product line in October 2025. The company’s gross profit also rose by 10.0% to $365.5 million, resulting in a gross profit margin of 62.0%, up from 59.4% in the prior year.
Despite the increase in sales and gross profit, Enovis reported a net loss of $8.5 million for the quarter, an improvement from the $55.7 million loss recorded in the same quarter last year. The loss from continuing operations was $8.4 million, compared to a loss of $55.6 million in the previous year. The company attributed the improved performance to higher gross profit, reduced amortization charges related to inventory step-up, and lower strategic transaction costs. Adjusted EBITDA for the quarter was $103.6 million, reflecting a margin of 17.6%, compared to $87.1 million and a margin of 15.5% in the prior year.
Operationally, Enovis has been active in strategic acquisitions and divestitures, completing seven transactions in 2025 for a total consideration of $36.9 million. These included acquisitions in both the Prevention & Recovery (P&R) and Reconstructive segments, aimed at enhancing product offerings and expanding distribution capabilities. The company also divested its Dr. Comfort product line, which did not represent a strategic shift but contributed to the overall financial results. The P&R segment reported net sales of $272.0 million, while the Recon segment saw a significant increase in sales to $317.1 million, driven by strong market demand and higher sales volumes.
Looking ahead, Enovis remains focused on leveraging its global footprint and enhancing its product portfolio through innovation and strategic investments. The company is committed to improving operational efficiencies and expanding its market presence, particularly in Europe and the Asia-Pacific region, where approximately 46% of its sales are generated. Enovis anticipates that ongoing investments in research and development, along with the integration of recent acquisitions, will support future growth and improve financial performance. The company maintains a strong liquidity position, with $33.1 million in cash and cash equivalents as of April 3, 2026, and significant borrowing capacity available under its credit facilities.
About Enovis CORP
Enovis Corporation is a medical technology company specializing in developing and distributing high-quality medical devices for reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention to recovery, serving healthcare professionals and consumers worldwide. The company emphasizes innovation, quality, and continuous improvement through its EGX management system, competing with leading global brands in fragmented, highly regulated markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.